Fulgent Genetics, Inc., a leading provider of comprehensive genetic testing and precision diagnostics, has released its Form 10-Q report for the second quarter of 2025. The report highlights significant financial growth and operational advancements, underscoring the company’s strategic focus on expanding its core laboratory services and therapeutic development.<\/p>\n
Financial Highlights<\/p>\n
Revenue: $81.8 million, increased by 15% from $71.0 million in the same period last year, driven by growth in precision diagnostics, anatomic pathology, and BioPharma services.<\/p>\n
Gross Profit: $34.4 million, increased by 30% from $26.5 million in the same period last year, reflecting improved cost structures and increased revenue.<\/p>\n
Operating Loss: $(19.7) million, slightly increased from $(18.9) million in the same period last year, due to higher operating expenses.<\/p>\n
Net Loss: $(19.3) million, increased from $(9.1) million in the same period last year, primarily due to an impairment loss and increased operating expenses.<\/p>\n
Net Loss Per Share: $(0.62), compared to $(0.29) in the same period last year, reflecting the increased net loss.<\/p>\n
Business Highlights<\/p>\n
Revenue Segments: The laboratory services segment saw significant growth across its product lines. Precision diagnostics revenue increased by 10% due to growth in reproductive health services and legacy diagnostic offerings. Anatomic pathology services revenue rose by 20%, driven by the absence of prior year disruptions and investments in digital pathology. BioPharma services experienced a 73% increase, attributed to the timing of service projects.<\/p>\n
Geographical Performance: Revenue from non-U.S. sources decreased by 18% in the three months ended June 30,\u00a02025, primarily due to a one-time licensing arrangement in the prior period that did not recur. The U.S. market remains the primary revenue driver, with significant contributions from domestic operations.<\/p>\n
Customer Concentration: A single customer accounted for 22% of total revenue in the three months ended June 30,\u00a02025, highlighting a concentration risk. Efforts are being made to diversify the customer base to mitigate this risk.<\/p>\n
Operational Efficiency: The company improved its gross margin from 37% to 42% year-over-year for the three months ended June 30,\u00a02025, through increased revenue and optimized cost structures.<\/p>\n
Future Outlook: The company does not expect future material revenues from COVID-19 testing services, indicating a strategic shift away from pandemic-related offerings. The focus will be on expanding core laboratory services and therapeutic development.<\/p>\n